Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Mar 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 279.13M | 313.90M | 322.42M | 284.39M | 230.47M | 163.46M |
Gross Profit | 206.55M | 239.58M | 252.65M | 223.38M | 178.64M | 118.36M |
EBITDA | -75.74M | -5.72M | 33.22M | 48.31M | 36.98M | 9.86M |
Net Income | -71.08M | -20.21M | 21.35M | 39.66M | 27.51M | 5.91M |
Balance Sheet | ||||||
Total Assets | 457.36M | 509.52M | 488.69M | 415.15M | 345.78M | 257.42M |
Cash, Cash Equivalents and Short-Term Investments | 222.76M | 230.49M | 220.73M | 211.64M | 199.71M | 152.45M |
Total Debt | 36.68M | 38.74M | 35.83M | 31.04M | 32.06M | 10.80M |
Total Liabilities | 107.39M | 112.19M | 102.74M | 82.71M | 87.22M | 60.19M |
Stockholders Equity | 349.97M | 397.33M | 385.95M | 332.44M | 258.56M | 197.22M |
Cash Flow | ||||||
Free Cash Flow | -13.68M | -7.67M | -3.59M | 17.61M | 30.32M | 12.55M |
Operating Cash Flow | -11.69M | 15.72M | 14.59M | 35.72M | 43.96M | 20.95M |
Investing Cash Flow | -40.05M | -59.22M | 74.35M | -156.38M | -13.64M | -8.40M |
Financing Cash Flow | 720.00K | 5.72M | 7.42M | 8.30M | 17.79M | 19.57M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
85 Outperform | $37.41B | 28.65 | 25.81% | 0.83% | 9.54% | 37.23% | |
76 Outperform | $191.29B | 79.71 | 15.94% | ― | 19.08% | 23.13% | |
63 Neutral | $9.12B | 116.65 | -23.93% | ― | -0.12% | -713.82% | |
62 Neutral | $4.38B | ― | -5.56% | ― | 11.94% | -6.98% | |
60 Neutral | $15.60B | 136.07 | -8.96% | 2.24% | -20.17% | -138.32% | |
54 Neutral | $837.98M | 55.81 | -19.14% | ― | -14.44% | -557.38% | |
51 Neutral | $7.44B | 0.40 | -61.90% | 2.33% | 17.14% | 1.55% |
On June 25, 2025, STAAR Surgical announced the appointment of Deborah Andrews as Chief Financial Officer, effective immediately. Andrews, who previously served as interim CFO since March 2025 and held various roles at STAAR, brings extensive experience and is expected to enhance financial and operational rigor. Additionally, STAAR established a new Capital Stewardship Committee to guide financial strategies, chaired by Lilian Y. Zhou, aiming to improve capital management and shareholder value. The company also restructured its investor relations function, resulting in the departure of Brian Moore, Vice President of Investor Relations and Corporate Development.
The most recent analyst rating on (STAA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On June 18, 2025, STAAR Surgical Company held its Annual Meeting of Shareholders where three proposals were voted upon. The shareholders elected six directors for terms expiring at the 2026 Annual Meeting, ratified the appointment of BDO USA, P.C. as the independent accounting firm for the fiscal year ending January 2, 2026, and approved the compensation of the Company’s executive officers on a non-binding advisory basis.
The most recent analyst rating on (STAA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
STAAR Surgical Company announced that its representatives will present to investors starting June 4, 2025, sharing insights on their strategic plans and financial performance. The presentation will highlight the company’s focus on innovative vision correction technologies and its commitment to addressing global myopia, with implications for continued growth and market leadership.
The most recent analyst rating on (STAA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On May 16, 2025, STAAR Surgical announced a $30 million share repurchase program, reflecting the board’s confidence in the company’s future and commitment to shareholder value. Additionally, on May 14, 2025, STAAR received approval from China’s National Medical Products Administration for its EVO+ Toric Implantable Collamer Lens, enhancing its market presence in China and aligning with its strategic priorities.
The most recent analyst rating on (STAA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
On May 7, 2025, STAAR Surgical reported its financial results for the first quarter ending March 28, 2025, revealing a 45% year-over-year decline in net sales to $42.6 million, primarily due to reduced channel inventory in China. Despite this, sales outside China grew by 9%, and the company implemented cost controls and restructuring to align expenses with sales, aiming to resume growth in revenue and Adjusted EBITDA in the second half of the year. The company is also mitigating tariff impacts through consignment agreements in China and expanding manufacturing capabilities in Switzerland. Regulatory approvals in Taiwan and Brazil for its EVO/EVO+ ICLs further strengthen its market position, although the company withdrew its previous financial outlook due to global economic uncertainties and evolving tariff policies.
On April 24, 2025, STAAR Surgical Company announced changes to its Board of Directors, appointing Louis E. Silverman as a director and noting that Aimee S. Weisner will not seek re-election. Wei Jiang will serve as a special strategic advisor to the Asia Pacific business, focusing on strengthening operations in the region. These changes aim to enhance STAAR’s strategic positioning and operational efficiency, particularly in the Asia Pacific market, amid evolving global tariff environments and distribution challenges.